Skip to main content

Development of new biotech AdvanceD materials based on Hyaluronic acid and nanoparticlEs to prevent Surgical adhesIons and pOst surgical infectionNs

Objective

The aim of the ADHESION Project is to strengthen the anti-adhesion and anti-bacterial characteristics of a NOVAGENIT® proprietary product (DAC®), by tuning and validating a new more competitive solution targeted to the orthopaedic and cardiovascular surgery. NOVAGENIT® will take the opportunity to expand its own business in the anti-adhesion market by taking advantage of the intrinsic barrier effect of the DAC® hydrogel. A new formulation of the DAC® product will add an anti-bacterial power to the anti-fouling/anti-adhesion intrinsic action. This could be due to a combination of silver nano-particles and to Vitamin C added to the derivatized hyaluronan based gel original formulation. The new formulation, comprising a lyophilized membrane, will increase the usability for the end user, and will prolong the shelf life of the biotech, advanced material product.NOVAGENIT® intends to address both the adhesion and infection issues, as it is a complete novelty in the market of anti-adhesion products. Specifically the business opportunity consists in the combination of the three key product features (anti-fouling, antibiotic and usability) into a novel product not yet market available, and to target two surgery markets (cardiovascular and orthopaedic ones) in order to generate the appropriate return on the investment.
This phase 1 consists in the feasibility study devoted to assess the economic/technological viability of the innovative idea and to generate its business plan. It will be followed by a phase 2 where the product will be industrialized and make ready for sales through a targeted marketing plan. The envisaged advantage for the European Health-care system from the results of the ADHESION Project is to spare the costs of re-interventions, both for the post-surgical adhesions (about 2 billion Euros/year), and the post-surgical infections (about 3 to 5 billion Euros/year). Future opportunities of this product on different markets will be exploited.

Field of science

  • /medical and health sciences/clinical medicine/orthopaedics
  • /medical and health sciences/clinical medicine/cardiology
  • /medical and health sciences/clinical medicine/surgery
  • /social sciences/economics and business/business and management/commerce
  • /natural sciences/chemical sciences/inorganic chemistry/inorganic compounds

Call for proposal

H2020-SMEINST-1-2014
See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

NOVAGENIT SRL
Address
Viale Trento 115/117
38017 Mezzolombardo
Italy
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000